Specific human leukocyte antigens (HLAs), notably HLA-B*27 and HLA-B*57 allele groups,
have long been associated with control of HIV-1. Although the majority of HIV-specific CD8 + …

Cytotoxic T-lymphocyte (CTL) responses peak coincident with the decline in acute HIV
viremia. Despite two reports of CTL-resistant HIV variants emerging during acute infection, the …

Cytolytic enzymes (CEs) are critical mediators of anti-viral and -tumor immunity; however, as
a number of molecules belong to this enzyme family, our understanding of CEs remains …

Cytotoxic T-lymphocyte (CTL) responses to human immunodeficiency virus arise early after
infection, but ultimately fail to prevent progression to AIDS. Human immunodeficiency virus …

Background Cytokine flow cytometry (CFC) or intracellular cytokine staining (ICS) can
quantitate antigen-specific T cell responses in settings such as experimental vaccination. …

Candidate HIV-1 vaccines currently being evaluated in clinical trials are designed to elicit
HIV-1-specific cellular immunity. Intracellular cytokine staining (ICS) assays allow sensitive, …

Interferon-gamma (IFN-γ) ELISpot and intracellular cytokine staining (ICS) assays are routinely
employed in clinical HIV vaccine trials to identify antigen-specific T cells in cryopreserved …

Galectin-9 (Gal-9) is a tandem repeat-type member of the galectin family and is a ligand for T-cell
immunoglobulin mucin domain 3 (Tim-3), a type-I glycoprotein that is persistently …

HIV-1-infected persons with HLA-B27 and-B57 alleles commonly remain healthy for
decades without antiretroviral therapy. Properties of CD8+ T cells restricted by these alleles …

Producing a prophylactic vaccine for human immunodeficiency virus (HIV) has proven to be
a challenge. Most biological isolates of HIV are difficult to neutralize, so that conventional …